Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377015111> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W4377015111 endingPage "13S" @default.
- W4377015111 startingPage "13S" @default.
- W4377015111 abstract "INTRODUCTION: Women with uterine fibroids (UFs) often experience heavy menstrual bleeding (HMB) and anemia. We report improvement in hemoglobin (Hgb) levels over time with elagolix (ELA) with estradiol 1 mg/norethindrone acetate 0.5 mg once-daily add-back (AB) therapy in women with UF-associated HMB. METHODS: This post hoc analysis from duplicate, IRB-approved, randomized, double-blind, placebo (PBO)-controlled, 6-month, phase 3 Elaris UF-1 and UF-2 studies (NCT02654054 and NCT02691494) evaluated ELA 300 mg twice daily plus AB versus PBO in women with UF-associated HMB. Hgb concentration (in grams/deciliter) was assessed monthly; no adjustment for multiple comparisons were made. All patients received ELA+AB in the pivotal and extension periods. Patients with baseline Hgb>10.5 g/dL but ≤12 g/dL were classified as “HgbLow” and Hgb≤10.5 g/dL as “Hgb≤10.5.” RESULTS: Baseline demographics were balanced between treatment groups. Overall, by month 1 of treatment, patients receiving ELA+AB (n=395) showed significant improvement in mean change in Hgb compared with PBO (n=196, P =.001). At month 6, 58.8% (HgbLow) and 35.7% (Hgb≤10.5) of patients reached Hgb>12 g/dL with ELA+AB versus 27.7% and 7.2% with PBO, respectively. Improvements in Hgb levels were sustained through 12 months (HgbLow, 59.6%; Hgb≤10.5, 46.3%). During the extension period, 49.3% of patients in the Hgb≤10.5 group treated with ELA+AB reached Hgb>12 g/dL at 9 months of treatment, with responses sustained through 12 months (ELA+AB/ELA+AB, 46.3%). 71.9% of patients in the HgbLow group reached Hgb>12 g/dL by 9 months, with responses sustained through 12 months (ELA+AB/ELA+AB, 59.6%). CONCLUSION: ELA+AB results in rapid, sustained improvement in Hgb levels in women with UF-HMB, regardless of starting Hgb levels." @default.
- W4377015111 created "2023-05-19" @default.
- W4377015111 creator A5010685115 @default.
- W4377015111 creator A5033968223 @default.
- W4377015111 creator A5082383884 @default.
- W4377015111 creator A5086298129 @default.
- W4377015111 creator A5090707540 @default.
- W4377015111 date "2023-05-01" @default.
- W4377015111 modified "2023-10-18" @default.
- W4377015111 title "Elagolix Improves Low Hemoglobin in Women With Uterine Fibroid-Associated Heavy Menstrual Bleeding: Post Hoc Analysis of Elaris UF-1 and UF-2 [ID: 1368055]" @default.
- W4377015111 doi "https://doi.org/10.1097/01.aog.0000929860.18306.99" @default.
- W4377015111 hasPublicationYear "2023" @default.
- W4377015111 type Work @default.
- W4377015111 citedByCount "0" @default.
- W4377015111 crossrefType "journal-article" @default.
- W4377015111 hasAuthorship W4377015111A5010685115 @default.
- W4377015111 hasAuthorship W4377015111A5033968223 @default.
- W4377015111 hasAuthorship W4377015111A5082383884 @default.
- W4377015111 hasAuthorship W4377015111A5086298129 @default.
- W4377015111 hasAuthorship W4377015111A5090707540 @default.
- W4377015111 hasConcept C126322002 @default.
- W4377015111 hasConcept C142724271 @default.
- W4377015111 hasConcept C144024400 @default.
- W4377015111 hasConcept C149923435 @default.
- W4377015111 hasConcept C204787440 @default.
- W4377015111 hasConcept C27081682 @default.
- W4377015111 hasConcept C2778248108 @default.
- W4377015111 hasConcept C2778917026 @default.
- W4377015111 hasConcept C2780084366 @default.
- W4377015111 hasConcept C2780566971 @default.
- W4377015111 hasConcept C29456083 @default.
- W4377015111 hasConcept C67761136 @default.
- W4377015111 hasConcept C71924100 @default.
- W4377015111 hasConcept C90924648 @default.
- W4377015111 hasConceptScore W4377015111C126322002 @default.
- W4377015111 hasConceptScore W4377015111C142724271 @default.
- W4377015111 hasConceptScore W4377015111C144024400 @default.
- W4377015111 hasConceptScore W4377015111C149923435 @default.
- W4377015111 hasConceptScore W4377015111C204787440 @default.
- W4377015111 hasConceptScore W4377015111C27081682 @default.
- W4377015111 hasConceptScore W4377015111C2778248108 @default.
- W4377015111 hasConceptScore W4377015111C2778917026 @default.
- W4377015111 hasConceptScore W4377015111C2780084366 @default.
- W4377015111 hasConceptScore W4377015111C2780566971 @default.
- W4377015111 hasConceptScore W4377015111C29456083 @default.
- W4377015111 hasConceptScore W4377015111C67761136 @default.
- W4377015111 hasConceptScore W4377015111C71924100 @default.
- W4377015111 hasConceptScore W4377015111C90924648 @default.
- W4377015111 hasIssue "5S" @default.
- W4377015111 hasLocation W43770151111 @default.
- W4377015111 hasOpenAccess W4377015111 @default.
- W4377015111 hasPrimaryLocation W43770151111 @default.
- W4377015111 hasRelatedWork W1957959321 @default.
- W4377015111 hasRelatedWork W1972032826 @default.
- W4377015111 hasRelatedWork W2216015926 @default.
- W4377015111 hasRelatedWork W2374911868 @default.
- W4377015111 hasRelatedWork W2495046245 @default.
- W4377015111 hasRelatedWork W2563828956 @default.
- W4377015111 hasRelatedWork W2748375747 @default.
- W4377015111 hasRelatedWork W2963035613 @default.
- W4377015111 hasRelatedWork W2997813250 @default.
- W4377015111 hasRelatedWork W3047389906 @default.
- W4377015111 hasVolume "141" @default.
- W4377015111 isParatext "false" @default.
- W4377015111 isRetracted "false" @default.
- W4377015111 workType "article" @default.